Aditxt, INC 8-K filings

Aditxt, Inc. has amended its Note Purchase Agreement, adding a new investor and issuing additional senior secured notes while canceling an existing note, maintaining the aggregate principal amount.

The Nasdaq Hearings Panel has denied Aditxt, Inc.'s request for continued listing, resulting in a suspension of trading effective June 25, 2026.

Aditxt, Inc. has entered into a definitive agreement to spin off its subsidiary, Ignite Proteomics, into a new publicly traded company via a merger with Copley Acquisition Corp.

Aditxt, Inc. has entered into a Note Purchase Agreement to issue senior secured convertible notes, consolidating existing debt and raising new capital.

Aditxt, Inc. announced the appointment of Jeffrey M. Busch as Interim CEO, replacing Amro Albanna, and detailed other executive and director resignations.

Aditxt, Inc. has received notice of non-compliance with Nasdaq stockholders' equity requirements, adding to existing delisting threats.

Aditxt, Inc. will implement a 1-for-27 reverse stock split effective May 18, 2026, primarily to regain compliance with Nasdaq's minimum bid price requirement.

Aditxt, Inc. has received a delisting notice from Nasdaq due to failure to maintain the minimum $1.00 bid price requirement.

Aditxt, Inc. shareholders approved the election of directors, auditor ratification, and granted authority for a reverse stock split of up to 1:250.

Aditxt, Inc. has issued $1.25 million in senior unsecured promissory notes to accredited investors, with specific redemption terms tied to equity offerings.

Aditxt, Inc. filed an amendment to its Form 8-K to provide the audited financial statements of Ignite Proteomics LLC and pro forma consolidated financial information following the acquisition.

Aditxt, Inc. has successfully regained compliance with Nasdaq's minimum stockholders' equity requirement.

Aditxt increased its at-the-market offering size by $36,800,000 to a total of $53,398,964, with approximately $21,257,000 sold to date under the program.

Aditxt, Inc. has completed the acquisition of Ignite Proteomics, a precision oncology company, for $36 million in preferred stock and $475,000 cash, simultaneously regaining compliance with Nasdaq's minimum stockholders' equity requirement.

Aditxt, Inc. will effect a 1-for-8 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement, effective March 9, 2026.

Aditxt, Inc. stockholders approved all eight proposals, including equity issuances, an employee stock plan, a reverse stock split, and an advisory name change to bitXbio, Inc.

Aditxt, Inc. adjourned its special meeting of stockholders to February 13, 2026, to allow more time for voting on proposals including stock issuances, equity plans, a name change, and a potential reverse stock split.

Aditxt, Inc. received an extension from Nasdaq to regain compliance with listing rules, contingent on completing financing transactions by May 15, 2026.

Aditxt, Inc. received a notice from Nasdaq regarding non-compliance with minimum stockholders' equity requirements, potentially leading to delisting.

Aditxt, Inc. details its bitXbio strategy, including a proposed name change to bitXbio, Inc., a planned Digital Asset Treasury, and updates on Pearsanta's IPO and Evofem's uplisting efforts.

Aditxt, Inc. announced a 1-for-113 reverse stock split, effective October 31, 2025, to meet Nasdaq's minimum bid price requirement.

Aditxt, Inc. announced the termination of its merger agreement with Evofem Biosciences, Inc. due to the end date passing and failure to obtain shareholder approval.

Aditxt, Inc. announced the appointment of Christopher J. Porcelli as General Counsel, Chief People Officer, and Corporate Secretary, effective September 30, 2025.

Aditxt, Inc. stockholders approved discretionary authority for a reverse stock split and re-elected five directors at their reconvened annual meeting.

Aditxt, Inc. issued $212,500 in senior unsecured notes at a discount and adjourned its annual meeting to vote on a reverse stock split and board elections.

Aditxt, Inc. and Evofem Biosciences, Inc. have signed Amendment No. 6 to their merger agreement, adjusting key terms for shareholder approval, dissenting shares, and introducing new Series A-2 Convertible Preferred Stock.

Evofem Biosciences reports significant financial challenges, including a going concern warning and multiple debt defaults, as its merger with Aditxt progresses with extended timelines and new investments.

Aditxt, Inc. CEO Amro Albanna outlined the company's 'acquire, build, capitalize' strategy, highlighting the upcoming Pearsanta IPO for early cancer detection and the pending Evofem acquisition.

Aditxt announces board member departures, a reduced board size, and sets its 2025 Annual Meeting date, while providing an update on the Evofem merger.

Aditxt, Inc. provided an update on its Adimune subsidiary, outlining its unique approach to autoimmune diseases and plans to initiate human clinical trials in the first half of 2026, alongside updates on other key spin-out opportunities.